Coherus Biosciences Inc


ASP | WAC | AWP at the HCPCS Unit


Coherus Biosciences Inc

Udenyca HCPCS:


HCPCS Code Descriptor:

Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg


Q Code

Udenyca NDCs:

70114-0120-01, 70114-0130-01, 70114-0101-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:


Package Type:


Route of Administration:


Udenyca CPT Codes:

Potential CPT administration codes for Udenyca can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Udenyca:

UDENYCA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Coherus Biosciences Inc and administered via the Subcutaneous route of administration. The Q Code: Q5111 is aligned to the drug UDENYCA.

Udenyca (pegfilgrastim) is an artificial protein that aids the production of white blood cells. It is used to help prevent patients from developing deficiency of these white blood cells. Udenyca is manufactured by Coherus Biosciences and is biosimilar to the drug Neulasta (J2506). Udenyca is aligned to the HCPCS code Q5111 and has been aligned to this code since January 2019. Patient assistance programs for this medication can be found through Coherus Solutions.


Q5111 Added Date:

January 1, 2019

Q5111 Effective Date:

April 1, 2023

Q5111 Termination Date:

HCPCS Active

Udenyca billing and coding information can be found through Coherus Biosciences Inc at the link below:
Udenyca patient assistance information can be found through Coherus Solutions at the URL:
UDENYCA prescribing information can be found at the link below:
Information regarding UDENYCA’s side effects can be found at MedlinePlus